Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market is Projected to: to Reach $38.26 Billion by 2029

 Developed by experienced analysts, this report offers in-depth insights for understanding competition and customer behavior in the programmed death (pd)-1 non-small cell lung cancer industry.

 

 How Much Is The Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Worth?
 The programmed death (PD)-1 non-small cell lung cancer market size has grown strongly in recent years. It will grow from $25.23 billion in 2024 to $27.50 billion in 2025 at a compound annual growth rate (CAGR) of 9.0%. The growth in the historic period can be attributed to increasing prevalence of non-small cell lung cancer, rising adoption of immunotherapy in developed nations, growing awareness about cancer screening, increasing approvals for monoclonal antibodies, and rising healthcare expenditure.
 
 The programmed death (PD)-1 non-small cell lung cancer market size is expected to see strong growth in the next few years. It will grow to $38.26 billion in 2029 at a compound annual growth rate (CAGR) of 8.6%. The growth in the forecast period can be attributed to increasing investments in cancer-specific infrastructure, expanding patient access to biologics in emerging markets, growing geriatric population globally, increasing reimbursement support for immunotherapies and rising clinical success rates of PD-1 inhibitors. Major trends in the forecast period include technological advancements in biomarker testing, developments in combination immunotherapy protocols, investment in personalized treatment strategies, research and development in novel PD-1 inhibitors and innovation in immune checkpoint blockade mechanisms.
 
 Get your free sample today:
 https://www.thebusinessresearchcompany.com/sample.aspx?id=25888&type=smp
 
  What Are The Current Leading Growth Drivers For Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market?
 The increasing adoption of personalized treatments is expected to propel the growth of the programmed death (PD)-1 non-small cell lung cancer market forward. Personalized treatments refer to medical approaches tailored to an individual’s genetic profile, lifestyle, and specific disease characteristics to achieve more effective and targeted outcomes. The rising demand for personalized treatments is due to the growing availability of genomic profiling and biomarker testing, as these technologies help identify specific mutations and biological markers, allowing clinicians to select therapies that are more likely to be effective for each individual. Personalized treatments help programmed death (PD)-1 non-small cell lung cancer (NSCLC) by tailoring therapies based on a patient’s genetic profile, tumor characteristics, and immune response. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based non-profit organization, the US Food and Drug Administration (FDA) approved 16 new personalized treatments for rare diseases in 2023 compared to 6 in the year 2022. Therefore, the increasing adoption of personalized treatments is driving the growth of the programmed death (PD)-1 non-small cell lung cancer market.
 
 Which Segment Accounted For The Largest Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Share?
 The programmed death (pd)-1 non-small cell lung cancer market covered in this report is segmented — 
 
 1) By Drug Type: Monotherapy, Combination Therapy
 2) By Line of Therapy: First-line Treatment, Second-line And Beyond
 3) By End User: Hospitals, Specialty Cancer Centers, Academic And Research Institutes, Other End Users
 
 Subsegments:
 1) By Monotherapy: Pembrolizumab (Keytruda), Nivolumab (Opdivo), Cemiplimab (Libtayo), Toripalimab, Tislelizumab, Camrelizumab, Dostarlimab, Other Monotherapy Drug Types
 2) By Combination Therapy: Programmed Death (PD)-1 Inhibitor And Chemotherapy, Programmed Death (PD)-1 Inhibitor And Cytotoxic T-Lymphocyte Associated Protein (CTLA)-4 Inhibitor, Programmed Death (PD)-1 Inhibitor And Vascular Endothelial Growth Factor (VEGF) Inhibitor, Programmed Death (PD)-1 Inhibitor And Targeted Therapy, Programmed Death (PD)-1 Inhibitor And Radiation Therapy, Triple Combination Therapy, Programmed Death (PD)-1 Inhibitor And Messenger Ribonucleic Acid (mRNA) Vaccine, Other Combination Drug Types
 
 Emerging Trends And Strategic Opportunities In The Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market
 Major companies operating in the programmed death (PD)-1 non-small cell lung cancer market are focusing on conducting clinical trials of innovative therapies, such as monotherapy, to improve outcomes for patients. Monotherapy is a treatment approach that uses a single drug or therapy to treat a disease or condition. For instance, in March 2025, Akeso, Inc., a China-based biopharmaceutical company, announced positive results from its Phase III HARMONi-2 trial evaluating Ivonescimab (AK112) in combination with chemotherapy for first-line treatment of advanced non-small cell lung cancer (NSCLC). The study met its primary endpoint by significantly extending progression-free survival compared to pembrolizumab, highlighting the dual-targeted bispecific antibody’s therapeutic potential.
 
 Which Are The Top Companies To Hold The Market Share In Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market?
 Major companies operating in the programmed death (pd)-1 non-small cell lung cancer market are F. Hoffmann-La Roche Ltd, Merck & Co. Inc., AbbVie Inc., Sanofi S.A., Novartis AG, GlaxoSmithKline plc, Regeneron Pharmaceuticals Inc., Incyte Corporation, Ono Pharmaceutical Co. Ltd., BeiGene Ltd., BioNTech SE, Shanghai Junshi Biosciences Co. Ltd., MacroGenics Inc., Akeso Inc., Arcus Biosciences Inc., Shandong Boan Biotechnology Co. Ltd., CStone Pharmaceuticals, iTeos Therapeutics Inc., Summit Therapeutics Inc., Shanghai Henlius Biotech Inc. 
 
 View the full programmed death (pd)-1 non-small cell lung cancer market report here:
 https://www.thebusinessresearchcompany.com/report/programmed-death-pd-1-non-small-cell-lung-cancer-global-market-report
 
 Which Region Is Projected To Account For The Largest Share Of The Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market?
 North America was the largest region in the programmed death (PD)-1 non-small cell lung cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the programmed death (pd)-1 non-small cell lung cancer market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
 
 Contact Us:
 
 The Business Research Company 
 
 https://thebusinessresearchcompany.com/ 
 
 Americas +1 310–496–7795
 Asia +44 7882 955267 & +91 8897263534
 Europe +44 7882 955267 
 
 Email: info@tbrc.info 
 
 
 Follow Us On:
 
 LinkedIn: https://in.linkedin.com/company/the-business-research-company